Genentech

Genentech, Inc. is a leading biotechnology company based in South San Francisco, California. Founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer, Genentech is known for its pioneering work in genetic engineering and biopharmaceuticals.

Genentech specializes in the development and manufacturing of innovative therapies to treat a wide range of medical conditions, including cancer, autoimmune diseases, infectious diseases, and rare genetic disorders. The company's portfolio includes groundbreaking drugs such as Herceptin (trastuzumab) for breast cancer, Avastin (bevacizumab) for various cancers, Rituxan (rituximab) for lymphoma and autoimmune diseases, and Lucentis (ranibizumab) for macular degeneration.

As a subsidiary of Roche Holding AG since 2009, Genentech operates as an independent entity within the Roche Group, leveraging Roche's global resources and infrastructure while retaining its entrepreneurial spirit and innovative culture. Genentech continues to invest heavily in research and development to advance its pipeline of novel therapies and improve patient outcomes.

With a commitment to scientific excellence, patient-centered innovation, and collaboration with healthcare partners, Genentech remains at the forefront of the biotechnology industry, striving to make a meaningful impact on the lives of patients worldwide.

Active/Inactive	Active
Headquater	San Francisco, California, California
Incorporation Year	1976(48 yrs old)
Industry	Biotechnology
Company Employees	10000+
Website	www.gene.com
Social Profile